XNYS · Healthcare Plans
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$89.01+4.41%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
34/100
Weak
Score components
TickerWhale View
CVS Health scores 34 out of 100 overall, which we rate weak. Sentiment Signal is its strongest area and Risk its weakest.
What helps
What to watch
- Technical
- Quality & growth
- Valuation
Quality & growth
30%34Weak
- Revenue growth 7.4%
- EPS growth 5.6%
Valuation
25%30Weak
- P/E 23.4
- EV/Sales 0.4
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates around 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 26 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.
#107 by market cap in our coverage · ~300,000 employees · Listed 1952-10-01 · www.cvshealth.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#129 / 139sector rank by TickerWhale Score
TickerWhale Score 34 vs sector average 54.6 (-20.6)
Revenue growth (industry)Top 63%
Gross margin (industry)Top 63%
Return on equity (industry)Top 75%
P/E (industry)Cheaper than 50%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
37/100Weak vs universe
Ranks 37th of 100 covered names on our technical composite — the composite itself scores 47/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
1 buy · 3 sell · 4 neutral of 8 votes
TickerWhale rates CVS's technical setup weak — 37th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
3 / 9constructive
- vs 200-day+0.1%
- vs 50-day-1.2%
Momentum
Mixed
- RSI (14)51 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength20· weak trend
- MACD (12,26,9)sell(histogram -0.476)
How the classic verdict is reached
Moving averages (9) agree on sell — 3 buy vs 4 sell — and carry one vote between them.
Oscillators (7) vote individually: 1 buy · 2 sell · 4 neutral.
Result — 1 buy vs 3 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)23.4
- P/S (TTM)0.3
- P/B1.4
- EV/EBITDA—
- EV/Sales0.4
- PEG4.19
Profitability & returns
- Gross margin13.6%
- Net margin1.2%
- ROE6.2%
- Debt/Equity0.77
Growth
- Revenue growth (YoY)7.4%
- EPS growth (YoY)5.6%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $114.6B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $402.1B | $372.8B | $357.8B |
| Gross profit | $55.4B | $51.4B | $54.4B |
| Operating income | $4.7B | $8.5B | $13.7B |
| Net income | $1.8B | $4.6B | $8.3B |
| EPS (diluted) | $1.39 | $3.66 | $6.47 |
| Free cash flow | $7.8B | $6.3B | $10.4B |
| Cash | $8.5B | $8.6B | $8.2B |
| Total debt | $80.0B | $82.9B | $79.4B |
| Equity | $75.2B | $75.6B | $76.5B |
| Net debt | $71.5B | $74.3B | $71.2B |
| Debt / equity | 1.06 | 1.10 | 1.04 |
| Liabilities / assets | 0.70 | 0.70 | 0.69 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CVSCurrentCVS Health | 34 | 47 | 23.4 | — | 1.4 | 0.4 | $89.01 | +4.41% | +7.4% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.